计算溶液所需的质量、体积或浓度。
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC 50 value of 6.3 nM for calcium influx.
In Vitro
MLN3126 inhibits CCL25-induced calcium mobilization with an IC 50 value of 6.3 nM in CCR9 expressing cells. MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC 50 of 14.2 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Invasion AssayCell Line: Mouse thymocytes Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3 μM Incubation Time: 90 min Result: Inhibited CCL25-induced chemotaxis of mouse thymocytes.
In Vivo
MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells . MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Activated T cell transferred colitis mouse model Dosage: 0.05, 0.25 and 1% (w/w) (around 4 g/day) Administration: Oral gavage; 21 days Result: Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.
Form:Solid